Iovance
IOVAMarket price data through November 12, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- -46%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$14
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- October 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 1 month
- How long Benson has been tracking this pick.
About Iovance
Iovance makes Amtagvi, a one-time cancer treatment built from a patient's own immune cells. Think of it as pulling the body's best fighters out of a tumor, growing an army of them in a lab, and sending them back in. It is the first approved treatment of its kind for advanced melanoma, and more than 1,000 patients have now received it.
The case for and against
Both sides of the story, in plain English.
- Record Revenue Rally
Revenue hit a record 122 million dollars this quarter, up about 80% from a year ago and 22% from just last quarter. Amtagvi made about 102 million of that, and the company now keeps about 60 cents of every sales dollar after production costs, its best ever. Management says it is on track for 410 to 420 million dollars in sales this year.
- Lung Cancer Leap
In lung cancer, 24.6% of 69 patients responded, nearly double the 12.8% seen with standard chemo. In a group picked using a tumor test, 59.1% responded, and the U.S. market for that group is about ten times the size of melanoma. The company plans to file for approval in 2027.
- Still Burning Cash
Over the past year, Iovance lost about 89 cents for every dollar of sales, though costs are coming down. It has 382 million dollars in the bank, which management says lasts well into 2029. But it has sold new shares to raise money before, which shrinks each owner's slice.
- One Product Problem
Amtagvi made about 102 million of the 122 million dollars in sales this quarter, so the company leans heavily on one treatment. The lung cancer filing is not planned until 2027, and the eye-popping 59% result came from a smaller, hand-picked group. A trial stumble or a new competitor could hit the stock hard.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-12. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch IOVA for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.